Related Experiment Videos
Effects of calcium entry blockade on hypertension-induced left ventricular hypertrophy
W H Frishman1, A E Skolnick, J A Strom
1Albert Einstein College of Medicine, Department of Medicine, Bronx, New York.
Insights
Calcium entry blockers effectively reduce left ventricular hypertrophy (LVH) in hypertensive patients. This regression of LVH may improve patient prognosis by mitigating risks associated with this common cardiac condition.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- Left ventricular hypertrophy (LVH) is a cardiac adaptation to increased demands, often caused by systemic hypertension.
- Hypertension-induced LVH leads to reduced myocardial compliance, altered structure, and impaired coronary perfusion.
- LVH is a significant risk factor for sudden cardiac death and other cardiovascular morbidities.
Purpose of the Study:
- To investigate the role of calcium entry blockers in achieving LVH regression.
- To explore the mechanisms underlying LVH regression induced by calcium entry blockers.
- To assess the potential impact of LVH regression on the prognosis of hypertensive individuals.
Main Methods:
- Review of experimental studies and clinical trials on calcium entry blockers and LVH.
- Analysis of hemodynamic and neurohumoral factors involved in LVH regression.
- Evaluation of left ventricular function following calcium entry blockade.
Main Results:
- Calcium entry blockers have demonstrated efficacy in causing LVH regression.
- The regression of LVH occurred without apparent deterioration of left ventricular function.
- Mechanisms for LVH regression involve complex hemodynamic and neurohumoral pathways, beyond simple vasodilation.
Conclusions:
- Calcium entry blockers are effective in regressing left ventricular hypertrophy in hypertensive patients.
- LVH regression induced by calcium entry blockers appears safe for left ventricular function.
- Regression of LVH may offer a favorable prognostic benefit for hypertensive patients.
Abstract:
Left ventricular hypertrophy (LVH) is a structural adaptation of the heart and is a response to increased hemodynamic and metabolic demands, which are most commonly caused by systemic hypertension. LVH induced by hypertension is associated with reduced myocardial compliance, structural alterations, and changes in coronary perfusion. Calcium entry blockers have caused LVH regression both in experimental studies and in clinical trials. Although their efficacy as antihypertensive agents is primarily due to their vasodilating properties, the mechanisms by which calcium entry blockers accomplish LVH regression are complex and include various hemodynamic and neurohumoral factors. Calcium entry blockade has decreased LVH with no apparent deterioration of left ventricular function. Because LVH is a major risk factor for sudden cardiac death and other cardiac morbidities, it is possible that the regression of LVH can improve the prognosis in hypertensive patients.